Supplement Documents for Financial Results Q2 FY12/21
Aug 13, 2021
To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs
Chiome Bioscience Inc.
Agenda
１．Overview of Q2 FY12/21 "Financial results"
２．Overview of Q2 FY12/21 "Operation highlights"
Appendix.
Corporate information
Pipeline information
2 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
Overview of
Q2 FY12/21 "Financial results"
Copyright © 2017 Chiome Bioscience Inc. All Rights Reserved.
3 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
Financial results: Profit and Loss
(JPY in millions)
Q2 FY2020 | Q2 FY2021 | Increase | ||||
(decrease) | ||||||
Net sales | 173 | 384 | 211 | |||
Drug Discovery & | 1 | 103 | 101 | • Upfront payment of the License | ||
Agreement with Shanghai Henlius | ||||||
Development | ||||||
Biotech, Inc. for LIV-2008/2008b | ||||||
Drug Discovery | 171 | 281 | 110 | • Growth in business with domestic | ||
Support | pharmaceutical companies | |||||
COS/SGA | 909 | 800 | (108) | |||
R&D Expense | 608 | 459 | (149) | • Decrease in the cost of study drug | ||
manufacturing and CRO in CBA-1205 | ||||||
program | ||||||
Other costs | 300 | 340 | 40 | • Up in material costs due to increased | ||
business transactions | ||||||
Operating Loss | (735) | (415) | 320 | |||
Ordinary Loss | (735) | (409) | 326 | |||
Net Loss | (736) | (408) | 327 | |||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | 4 |
Financial results: Balance Sheet
(JPY in millions) | |||
As of | Dec. 31, | As of Jun. 30, | |
2020 | 2021 | ||
Current assets | 3,248 | 3,087 | |
（Cash on hand in banks) | 2,686 | 2,301 | |
(Other current assets) | 562 | 786 | |
Non-current assets | 246 | 241 | |
Total assets | 3,494 | 3,328 | |
Current Liabilities | 342 | 427 | |
Non-current liabilities | 41 | 42 | |
Total liabilities | 384 | 469 | |
Total net assets | 3,109 | 2,858 | |
Total liabilities and net assets | 3,494 | 3,328 | |
5 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
This is an excerpt of the original content. To continue reading it, access the original document here.